Safety Profiles Prescription GLP-1 medications carry well-documented side effect profiles
Administering a 2.4 mg dose resulted in an average weight loss of 6% over a three-month period
Fiber strategy: Increase gradually to avoid bloating
FDA's April 30, 2026 Proposal On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances when FDA-approved versions are available
The demographic variables included in weighting for the general population sample are sex, age, education, race/ethnicity, region, civic engagement, frequency of internet use, political party identification by race/ethnicity, and education
Theyre not FDA-regulated, theres no good evidence they work for weight loss, and honestly, theyre just going to waste your money and delay you from getting real help
